Immunai vs TrialJectory

Immunai vs TrialJectory, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Immunai is on 69/100 and TrialJectory on 58/100.

Immunai logo
ImmunaiMapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
Try Immunai
TrialJectory logo
TrialJectoryAI-powered platform connecting cancer patients to advanced treatments and clinical trials.
Try TrialJectory

Where each one leads

Immunai

  • our overall score: 69/100 against 58/100
  • domain rating: 46/100 against 39/100
  • headcount: 179 against 17
  • headcount growth: +13.0% against -33.1%
  • funding raised: $295M against $39.7M
  • LinkedIn following: 26,832 against 4,387

TrialJectory

Leads on none of the measures we hold for both companies.

At a glance

MeasureImmunaiTrialJectory
What it isMapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.AI-powered platform connecting cancer patients to advanced treatments and clinical trials.
CategoryHealthcare, Immunology, Data, AnalyticsHealthcare, Clinical Trials, Cancer, HealthTech
Sells toBusiness modelB2BB2B
OfferingSoftwareSoftware
Founded20192017
HeadquartersNew York, United StatesNew York, United States
StatusActiveActive

Size, funding and growth

MeasureImmunaiTrialJectory
Employees17917
Headcount growthLast 12 months+13.0%-33.1%
Total funding$295M$39.7M
Latest roundSeries BSeries A
Valuation$1.0BNot published
LinkedIn followers26,8324,387

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureImmunaiTrialJectory
StartupHub scoreOur 0-100 rating69/10058/100
Traction60/10051/100
Team70/10070/100
Search visibility39/10036/100
Quality78/10062/100
Agent readinessHow well an AI agent can read and act on the siteF (32/100)F (32/100)
Domain ratingLink authority, 0-10046/10039/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureImmunaiTrialJectory
HostingNot detectedAWS
CDNNot detectedCloudFront
CMSWordPressNot detected
FrameworksJquery, BootstrapNext.js
AnalyticsGoogle Tag ManagerNot detected

Immunai vs TrialJectory: common questions

Which is better, Immunai or TrialJectory?

On our 0-100 score Immunai rates higher (69/100 against 58/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.

How do Immunai and TrialJectory compare on the numbers?

Immunai leads on our overall score (69/100 against 58/100), domain rating (46/100 against 39/100), headcount (179 against 17), headcount growth (+13.0% against -33.1%), funding raised ($295M against $39.7M), LinkedIn following (26,832 against 4,387).

Read the full Immunai review and pricing or the TrialJectory review and pricing. You can also browse other Immunai alternatives we track.